In all manufacturing，The phenomenon of the drug industry is an extreme。Development of new drugs，Regardless of difficulty，cycle，Still capital investment，More difficult than ordinary manufacturing，R & D success rate is lower。is a typical "capital -intensive+talent dense" industry。and the recently promulgated biomedical country 12th Five -Year Plan，It seems to make people see a front -line dawn: according to the plan，2015，my country's pharmaceutical industry must achieve 3 trillion total output value。

 

This number is 2 times of 2009。If the Chinese biomedical industry can use this to realize the stake betting apptransformation stake sports betting appfrom Made in China to Invented in China，This will be our biological、A rare major breakthrough in the history of the pharmaceutical industry。In view of this，We need to understand the production of biomedicine in my country、The status quo of the research and some approximate situation in the pharmaceutical market。

 

Like other manufacturing，my country's pharmaceutical industry is mainly concentrated in the production and sales of low -end products，Low -end and homogeneity is two typical features，Products are mainly raw materials and preparations，To expand the scale to reduce costs，The main competitive advantage brought about the low labor costs brought about by the lack of population dividends and union functions。Overall，Chinese drug manufacturing, although GDP is high，But the actual gold content is not high。

 

If the field of biomedical circulation is fully marketized，Medical system to provide service pricing instead of making money by selling medicines，Then the competition of the pharmaceutical factory will be extremely cruel，The closure of large -scale small and medium -sized pharmaceutical plants can be expected。This is very similar to the domestic computer industry in my country: the gross profit of retail companies is only about 5%。The profit of the manufacturer is not high，Most profits are divided by chip and installation operating system software manufacturers，seemingly high -tech，In fact, it is just a high stake sports betting appStake Sports Betting-tech product assembly。

 

If you do not carefully analyze the core competitiveness of the drug industry and the external environment，So we can easily ignore the truth，Falling into some kind of self -comfort and encouragement，As can be seen everywhere on the Internet: "By 2013, China will surpass Japan to become the world's second pharmaceutical country，China will also exceed the United States by 2020，Leap to the world's No. 1 Medicine Power "。Local pharmaceutical companies are wandering in the low position of drug research and development。Lack of R & D capabilities、Scarce of funds and disorderly market competition and a long R & D cycle make companies more willing to earn a little profit from processing。Research and development，Still belonging to a very small number of big companies。

 

If my country -made biomedicine, if you want to successfully change from simple manufacturing to "manufacturing and research and development"，Gradually increasing the importance and investment in R & D is inevitable，In addition, you also need to use advanced methods and technology，Improve the input and output ratio of resources。Fortunate is，We have seen that we have seen that my country ’s drug research and development institutions already have a certain basic technical strength。

 

In recent years，More and more international large -scale contract research institutions (CRO) began to enter China，Giant Kuntai Company, the global pharmaceutical Stake Sports Bettingstake online sports bettingclinical research field、Textus, etc. in Beijing、Shanghai and other first -tier cities set up branches。Local CROs also gradually grow，China's local drug research and development outsourcing service industry is experiencing a high -speed development period，In just five or six years，China has emerged hundreds of companies engaged in clinical trial services，Mainly providing compound research、Study on Materials and Drugs、Research and development outsourcing work in the fields of pre -clinical research and clinical research in preparations，An optional service provider developed as an outsourced outsourcing in an international drug giant。

 

Global Pharmaceutical Market，Biomedical R & D market outsourcing market has become a new stage for many companies to compete。At present, the global CRO's market value is about 20 billion US dollars，It is expected that it will reach US $ 36 billion by 2010。Medical companies in developed countries under the huge cost pressure of new drugs，It is vigorously cut R & D expenditure，Reduce research and development costs through outsourcing。

 

Another aspect，my country's drug research and development industry's understanding of the theory and practice of test design (DOE)，Also staying at a higher level。Light resources are not enough，If you want to be a big clinical research and medical research and development，An important、Essential strategy，It is the most advanced test method and analysis method stake sports betting appstake online sports bettingto introduce。August 2007，my country's CRO leading company Yao Ming Kant, who has nearly 3,000 researchers, successfully landed on the NYSE，The income of the year was as high as $ 135 million，Market value exceeds $ 1.1 billion。